Genmab — Oktober 2024
-
Genmab licenses Revitope's dual-antigen T-cell tech in $600M+ deal https://firstwordpharma.com/story/5907650
-
Revitope press release - Revitope Enters into a License Agreement for Next-generation T Cell Engagement Technology https://www.prnewswire.com/news-releases/revitope-enters-into-a-license-agreement-for-next-generation-t-cell-engagement-technology-302290430.html?utm_source=dlvr.it&utm_medium=twitter
-
novartis q3-2024-earnings-call-transcript https://www.fool.com/earnings/call-transcripts/2024/10/29/novartis-ag-nvs-q3-2024-earnings-call-transcript/ Kesimpta -We're annualizing now well above $3 billion, and have the opportunity, I think, to well exceed our $4 billion peak sales guidance to date.
-
EL 15.12: seems they have been working on this since 2021. Are part 1 completed and now part 2 . https://institut-curie.org/clinical-trial/gct1047-01
-
8 Super Gems Found, Out of 100+ Stocks (Quality + Hyper Growth + Deep Value + High Cashflow) https://www.youtube.com/watch?v=ude3-6H8GtM
-
Implementeringen af AI i kliniske forsøg kan faktisk påvirke rekrutteringsstrategierne for patienter. AI-teknologier kan muligvis strømline processer, forbedre målretning af patienter eller forbedre dataanalyse, hvilket potentielt kan føre til mere effektiv rekruttering.
-
Hvis AI-værktøjerne dog ikke er blevet ordentligt integreret, eller hvis der har været problemer med at målrette den rigtige patientpopulation, kan det også bidrage til lavere rekrutteringsnumre. Desuden, hvis studiekravene er blevet mere strenge på grund af AI-drevne indsigter, kan det begrænse antallet af kvalificerede deltagere. Det ville være nyttigt at se efter specifik information i de kommende opdateringer for at forstå AI's indvirkning på rekrutteringen til GEN1047.
-
-
Optimizing clinical trials
Clinical trials are essential for evaluating the safety and efficacy of new treatments. Yet they can be lengthy, costly and challenging. Genmab is using AI to optimize the clinical trials process, applying the technology to help identify suitable patient populations, streamline the recruitment process, and design and execute trials more efficiently. -
translating this https://medical.nikkeibp.co.jp/leaf/all/cancernavi/news/202410/586322.html gave some results , best in english- During the median follow-up period of 13.7 months, the median OS was 15.0 months (95% CI: 9.7-NE) in the TV group and 8.5 months (95% CI: 6.8-10.6)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind